Phase 2 BRAF Clinical Trials
11 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–11 of 11 trials
Recruiting
Phase 2
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
BRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more
University of California, San Francisco96 enrolled5 locationsNCT07110246
Recruiting
Phase 1Phase 2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Solid TumorsHGGCancer Harboring BRAF Alterations+1 more
Fore Biotherapeutics254 enrolled67 locationsNCT05503797
Recruiting
Phase 2
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
BRAF V600E
Tianjin Medical University Cancer Institute and Hospital49 enrolled4 locationsNCT07506109
Recruiting
Phase 2
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
Colorectal NeoplasmsBRAFRAS
Zhejiang University70 enrolled1 locationNCT07257653
Recruiting
Phase 2
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
Northwestern University43 enrolled1 locationNCT05576896
Recruiting
Phase 2
Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
Melanoma BRAF V600E/K MutatedMelanoma and Brain Metastases
Grupo Español Multidisciplinar de Melanoma33 enrolled18 locationsNCT06887088
Recruiting
Phase 2
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
BRAF V600 Colorectal Cancer
Sun Yat-sen University20 enrolled1 locationNCT07150247
Recruiting
Phase 1Phase 2
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
RAS/BRAF Wild Type Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.72 enrolled27 locationsNCT07044908
Recruiting
Phase 2
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
BRAF V600E Mutation PositiveAmeloblastoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University12 enrolled1 locationNCT06653517
Recruiting
Phase 2
Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
Unresectable Colon Cancer Peritoneal MetastasesPMMR/Ras/BRAF Wild-type
Second Affiliated Hospital, School of Medicine, Zhejiang University30 enrolled1 locationNCT05742425